New hope for rare blood disease: drug cocktail targets stubborn cases
NCT ID NCT07204041
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 30 times
Summary
This study tests a three-drug combination (selinexor, thalidomide, and dexamethasone) in 40 adults with Langerhans cell histiocytosis that did not improve or came back after standard treatment. The goal is to see if the regimen can control the disease and delay progression. Participants will be followed for side effects and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LANGERHANS CELL HISTIOCYTOSIS (LCH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, beijing,
Beijing, China
Conditions
Explore the condition pages connected to this study.